Orthotopic administration of (213)Bi-bevacizumab inhibits progression of PC3 xenografts in the prostate.
OBJECTIVE
To investigate orthotopic targeted α-radioimmunotherapy for the control of early-stage PC3 prostate cancer nude mouse xenografts using the radiolabeled bevacizumab (BZ) immunoconjugate ((213)Bi-BZ), which emits short-range α-radiation.


METHODS
10(6) PC3 human prostate cancer cells were injected into the lower capsule of the mouse prostate gland 1 week prior to α-radioimmunotherapy. Mice were euthanized and assessed for tumour growth at 2 (two mice), 4 (two mice) and 6 weeks (three mice) post-therapy. The no-therapy control mice received a saline injection in equal volume to each BZ administration.


RESULTS
(213)Bi-BZ is significantly more efficacious in inhibiting xenograft progression in the prostate gland compared with BZ alone (p = 0.009) and when compared with the 'no therapy' protocol (p < 0.0001).


CONCLUSIONS
Orthotopic administration of (213)Bi-BZ greatly improves the early control of organ-confined prostate cancer compared with BZ alone (p < 0.01).
Cancer Pathology & Cell Biology Laboratory, Ingham Institute of Applied Medical Research, & Discipline of Pathology, University of Western Sydney School of Medicine, Liverpool 2170, Australia.
Sma
S
Rizvi
Bj
B
Allen
Cs
C
Lee
F
F
Bruchertseifer
C
C
Apostolidis
A
A
Morgenstern
Ra
R
Clarke
D000230:Adenocarcinoma / Q000532:radiotherapy*; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D011467:Prostate / Q000187:drug effects* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology; D023041:Xenograft Model Antitumor Assays
D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab